DK2560672T3 - RTEF-1-varianter samt deres anvendelser - Google Patents

RTEF-1-varianter samt deres anvendelser Download PDF

Info

Publication number
DK2560672T3
DK2560672T3 DK11716776.7T DK11716776T DK2560672T3 DK 2560672 T3 DK2560672 T3 DK 2560672T3 DK 11716776 T DK11716776 T DK 11716776T DK 2560672 T3 DK2560672 T3 DK 2560672T3
Authority
DK
Denmark
Prior art keywords
rtef
seq
cell
polypeptide
ser
Prior art date
Application number
DK11716776.7T
Other languages
English (en)
Inventor
Anna Dye
Timothy J Stout
Binoy Appukuttan
Trevor Mcfarland
Original Assignee
Res Dev Foundation
Univ Oregon Health & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation, Univ Oregon Health & Science filed Critical Res Dev Foundation
Application granted granted Critical
Publication of DK2560672T3 publication Critical patent/DK2560672T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Isoleret RTEF-1-polypeptid-variant, som reducerer VEGF-promotoraktivitet, omfattende en aminosyresekvens, der er mindst 80% identisk med de sammenhængende aminosyrer 1) aminosyrerne 24 til 47 i SEQ ID NO: 15 og 2) hver af SEQ ID NOs: 16 og 17, men ikke omfatter de sammenhængende aminosyrer i SEQ ID NOs: 8, 9, 11 og 12, idet polypeptidet endvidere ikke indeholder en aminosyresekvens bestående af aminosyrerne 1-16 i SEQ ID NO: 8.
2. Isoleret RTEF-1-polypeptid-variant ifølge krav 1 omfattende en aminosyresekvens, der er mindst 85%, 90%, 95%, 97% eller 99% identisk med de sammenhængende aminosyrer 1) aminosyrerne 24 til 47 i SEQ ID NO: 15 og 2) hver af SEQ ID NOs: 16 og 17.
3. Isoleret RTEF-1-polypeptid-variant ifølge krav 1 eller 2, hvori polypeptidet er mindst 95%, 97% eller 99% identisk med SEQ ID NO: 1 eller omfatter SEQ ID NO: 1, eller hvori polypeptidet er mindst 95%, 97% eller 99% identisk med SEQ ID NO: 2 eller omfatter SEQ ID NO: 2.
4. Isoleret RTEF-1-polypeptid-variant ifølge et hvilket som helst af kravene 1 til 3, hvori polypeptidet ikke omfatter de sammenhængende aminosyrer i SEQ ID NOs: 8, 9, 11 og 12.
5. Isoleret RTEF-1-polypeptid ifølge et hvilket som helst af kravene 1 til 4, hvori polypeptidet er mindst 95%, 97% eller 100% identisk med SEQ ID NO: 1, eller hvori polypeptidet er mindst 95%, 97% eller 100% identisk med SEQ ID NO: 2.
6. Isoleret RTEF-1-polypeptid ifølge et hvilket som helst af kravene 1 til 5, som endvidere omfatter en celleinternaliseringsenhed eller en kernelokaliseringssekvens, som er et polypeptid, et antistof, en aptamer eller en avimer.
7. Isoleret RTEF-1-polypeptid ifølge et hvilket som helst af kravene 1 til 6, som endvidere omfatter et cellesekretionssignal.
8. Nukleinsyre omfattende et nukleinsyresegment, der koder for en RTEF-1 -polypeptid-variant ifølge et hvilket som helst af kravene 1 til 7.
9. Nukleinsyre ifølge krav 8, hvor nukleinsyren er omfattet af en vektor, fortrinsvis en adenovirusvektor, en adenoassocieret virusvektor, en herpesvirusvektor, en SV-40-virusvektor, en retrovirusvektor eller en vacciniavirusvektor.
10. Farmaceutisk sammensætning omfattende a) én eller flere RTEF-1-polypeptid-varianter som anført i et hvilket som helst af kravene 1 til 7 eller én eller flere nukleinsyrer som anført i et hvilket som helst af kravene 8 til 9; og b) et farmaceutisk acceptabelt bærestof.
11. Farmaceutisk sammensætning ifølge krav 10 omfattende SEQ ID NO: 1 eller SEQ ID NO: 2 eller en nukleinsyre, der koder for SEQ ID NO: 1 eller SEQ ID NO: 2.
12. Farmaceutisk sammensætning ifølge krav 10 eller 11 til anvendelse ved behandling af et individ med en lidelse, der står i forbindelse med abnorm cellevækst eller abnorm celleproliferation.
13. Farmaceutisk sammensætning ifølge krav 12, hvor den med abnorm cellevækst eller abnorm celleproliferation forbundne lidelse er en angiogen lidelse, som er cancer, okulær neovaskularisering, en arteriel-venøs misdannelse, koronar restenose, restenose i perifere kar, glomerulonephritis eller arthritis rheumatoides.
14. Farmaceutisk sammensætning ifølge krav 13, hvor den angiogene lidelse er cancer eller okulær neovaskularisering.
DK11716776.7T 2010-04-19 2011-04-19 RTEF-1-varianter samt deres anvendelser DK2560672T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32567510P 2010-04-19 2010-04-19
PCT/US2011/032994 WO2011133512A1 (en) 2010-04-19 2011-04-19 Rtef-1 variants and uses thereof

Publications (1)

Publication Number Publication Date
DK2560672T3 true DK2560672T3 (da) 2014-03-17

Family

ID=44170031

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11716776.7T DK2560672T3 (da) 2010-04-19 2011-04-19 RTEF-1-varianter samt deres anvendelser

Country Status (5)

Country Link
US (3) US8785385B2 (da)
EP (1) EP2560672B1 (da)
CA (1) CA2796601C (da)
DK (1) DK2560672T3 (da)
WO (1) WO2011133512A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206423B2 (en) * 2012-12-30 2015-12-08 The Regents Of The University Of California Methods of modulating compliance of the trabecular meshwork
WO2015130783A1 (en) * 2014-02-25 2015-09-03 Research Development Foundation Sty peptides for inhibition of angiogenesis
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102826798B1 (ko) * 2021-10-01 2025-07-02 연세대학교 산학협력단 Dna 손상 복구 효율 조절용 조성물
US20250340871A1 (en) * 2021-10-01 2025-11-06 Industry-Academic Cooperation Foundation, Yonsei University Composition for controlling dna damage repair efficiency

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5811103A (en) * 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
DE69334225D1 (de) 1992-07-07 2008-07-31 Japan Tobacco Inc Verfahren zur transformation einer monokotyledon pflanze
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
WO1994002620A2 (en) 1992-07-27 1994-02-03 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
WO1995020975A1 (en) 1994-02-04 1995-08-10 The Regents Of The University Of California Tef-1 isoforms and uses thereof
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US7183388B2 (en) 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
EP1412493B1 (en) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
US7850959B2 (en) 2003-10-10 2010-12-14 Beth Israel Deaconess Medical Center Methods and compositions for treating conditions involving abnormal angiogenesis
CA2553676A1 (en) 2004-01-28 2005-08-11 Research Development Foundation Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
JP2008528633A (ja) 2005-02-01 2008-07-31 リサーチ ディベロップメント ファウンデーション Ｂｌｙｓレセプターを標的化するためのｂｌｙｓ融合タンパク質およびｂ細胞増殖性疾患の処置方法
JP4177863B2 (ja) 2006-08-08 2008-11-05 本田技研工業株式会社 車両用エンジンの制御装置
DK2170938T3 (da) 2007-06-06 2012-07-16 Res Dev Foundation RTEF-1-varianter samt deres anvendelse til inhibering af angiogenese

Also Published As

Publication number Publication date
US9650426B2 (en) 2017-05-16
CA2796601A1 (en) 2011-10-27
US20120063994A1 (en) 2012-03-15
CA2796601C (en) 2019-03-26
EP2560672A1 (en) 2013-02-27
WO2011133512A1 (en) 2011-10-27
US8785385B2 (en) 2014-07-22
US20140357704A1 (en) 2014-12-04
US20170233444A1 (en) 2017-08-17
EP2560672B1 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
US9650426B2 (en) RTEF-1 variants and uses thereof
US9937269B2 (en) RTEF-1 variants and the use thereof for inhibition of angiogenesis
JP7369039B2 (ja) 標的化タンパク質分解
Marasco Intrabodies: turning the humoral immune system outside in for intracellular immunization
DK2970512T3 (da) Immunmodulatoriske fusionsproteiner og fremgangsmåder til fremstilling deraf
US20180372750A1 (en) Antibody and antibody mimetic for visualization and ablation of endogenous proteins
Leonard et al. Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity
AU2021328359B2 (en) Modified porcine pancreatic elastase proteins
WO2017134592A1 (en) Anti-cd20/immunomodulatory fusion proteins and methods for making same
US20250197472A1 (en) Programmable immunocyte receptor complex system
CN117715648A (zh) 靶向uPAR的抗原识别受体和其用途
JP2024532486A (ja) Ｄｌｌ３を標的とする抗原認識受容体及びその使用
WO2022174781A1 (zh) 多结构域融合蛋白及其应用
US20170037091A1 (en) Sty peptides for inhibition of angiogenesis
WO2023164266A2 (en) Dual checkpoint inhibitors and methods of using the same
CN118139892A (zh) 一种三靶点抗肿瘤药物、其制备方法及其应用